Nov-30-04 02:44pm

From-ALLERGAN LEGAL DEPARTMENT

+17142464249

T-329 P.01

F-755

FILE COPY

Docket 17322CON2CIP1 (AP)

# **CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

Date: November 30, 2004

Pages, including this Cover Sheet: 5

I hereby certify that this <u>Request for Correction of Filing Receipt</u> (2 pages) and a copy of the Filing Receipt (2 pages) are being facsimile transmitted to the Initial Patent Examination's Filing Receipt Corrections, United States Patent and Trademark Office at 7,03-746-9195 on NOVEMBER 30, 2004.

Susan Bartholomew

Typed or printed name of person signing Certificate

COMMENTS:

In Re Application: E. B. DREYER, et al.

Application Serial No.: 10/734,930

Filed: December 12, 2003

Title: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE RETINAL

DISEASES

From: AGENT

BRENT A. JOHNSON

Registration No. 51,851

Telephone No. (714) 246-4348 Facsimile No. (714) 246-4249

Allergan, Inc.

2525 Dupont Drive, T2-7H

Irvine, CA 92612

Docket No. 17322 CON2CIP (AP)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Dreyer, et al.

Examiner:

Serial Number: 10/734,930

Group Art: 1614

Filed: December 12, 2003

Confirmation No. 2241

For: CALCIUM BLOCKERS TO TREAT

PROLIFERATIVE RETINAL DISEASE

Irvine, California

## Request for Correction of Filing Receipt

Initial Patent Examination's Filing Receipt Corrections Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Dear Sir:

- 1. This is a request for correction to a filing receipt. Under the first line of "Domestic Priority data as claimed by applicant, please correct "This application is a CON of 10/436,902 05/12/2003" to read "This application is a CIP of 10/436,902 05/12/2003."
- A marked copy of the receipt is enclosed herewith.
- 3. The Commissioner is hereby authorized to charge any additional and necessary fees as required to process this request, or to credit any overpayment, to Deposit Account number 01-0885.

Respectfully submitted,

Date: November 30, 2004

Agent of Record

Registration Number 51,851

Date: November 30, 2004

17322CON2CIP1 (AP)

Serial No. 10/734,930

Please direct all correspondence and inquiries to:

Brent A. Johnson Allergan, Inc. 2525 Dupont Drive, T2-7H Irvine, California 92612 Tel: 714 246-4348 Fax: 714 246 4249

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that this Transmittal Letter for Correction of Filing Receipt Parts and the 2 page attachment is being facsimile transmitted to the Initial Patent Examination's Filing Receipt Corrections, United States Patent and Trademark Office, Facsimile Number 703-746-9195 on November 30, 2004.

Name of person mailing paper

Signature of person mailing paper

OCT 1 2 2004



## United States Patent and Trademark Office

## LEGAL/PATENTS

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Offices

Address COMMISSIONER FOR PATENTS

P.O. Des 1450

Alexandria, Vagnila 22313-1430 y. Vingueis 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS	
10/734 930	12/12/2003	1614	900	17322 CON2CIP (AP)		18	2	

BRENT A. JOHNSON ALLERGAN, INC. 2525 Dupont Drive, T2-7H Irvine, CA 92612

**CONFIRMATION NO. 2241 UPDATED FILING RECEIPT** "OC00000001 4004594"

Date Mailed: 10/05/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Evan B. Dreyer, Upper St. Clair, PA; Scott M. Whitcup, Laguna Hills, CA; William A. Hare, Tustin, CA; Cun Jian Dong, Irvine, CA;

#### Power of Attorney:

Martin Voet-25208 ROBERT J. BARAN-25806 Stephen Donovan-33433 Carlos A. Fisher-36510 Brent Johnson-51851

Dean Stathakis-54465

# Domestic Priority data as claimed by applicant

This application is a CON-of 10/436,902 05/12/2003 which is a CON of 10/038,215 01/02/2002 PAT 6,573,280 which is a CON of 09/445,832 12/13/1999 PAT 6,380,261 which is a 371 of PCT/US98/12414 06/15/1998 which claims benefit of 60/051,962 06/30/1997

#### Foreign Applications

If Required, Foreign Filing License Granted: 03/22/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,

PAGE 4/5 \* RCVD AT 11/30/2004 4:44:10 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-2/2 \* DNIS:7469195 \* CSID:+17142464249 \* DURATION (mm-ss):01-42//

## US10/734,930

Projected Publication Date: 01/13/2005

Non-Publication Request: No

Early Publication Request: No

Title

Calcium blockers to treat proliferative retinal diseases

**Preliminary Class** 

514

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

 RESPONSE DUE Z

Filing